Cargando…

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

BACKGROUND: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chemotherapy, best supportive care (BSC), and hypomethylating agents. Currently, limited data is available on hypomethylating agents in older AML patients in unselected patient populations. METHODS: To co...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Helm, Lieke H, Scheepers, Ellen RM, Veeger, Nic JGM, Daenen, Simon MGJ, Mulder, André B, van den Berg, Eva, Vellenga, Edo, Huls, Gerwin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639930/ https://www.ncbi.nlm.nih.gov/pubmed/23587459 http://dx.doi.org/10.1186/1756-8722-6-29

Ejemplares similares

The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis
por: de Boer, Bauke, et al.
Publicado: (2020)

ELMO1 Is Upregulated in AML CD34+ Stem/Progenitor Cells, Mediates Chemotaxis and Predicts Poor Prognosis in Normal Karyotype AML
por: Capala, Marta E., et al.
Publicado: (2014)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia
por: in 't Hout, Florentien E. M., et al.
Publicado: (2020)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML
por: Hilberink, Jacobien, et al.
Publicado: (2023)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
por: Almeida, António, et al.
Publicado: (2016)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
por: Pan, Hong, et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
por: de Jong, Mathilde R. W., et al.
Publicado: (2018)

Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA)
por: van Veen, Lucia, et al.
Publicado: (2013)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
por: Grimm, Juliane, et al.
Publicado: (2022)

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

The rotational structure of $^{227}$Ra
por: Von Egidy, T, et al.
Publicado: (1981)

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones
por: Houtsma, Roos, et al.
Publicado: (2022)

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis
por: Buitenwerf, Edward, et al.
Publicado: (2015)

Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study
por: Hazenberg, Carin L. E., et al.
Publicado: (2022)

Familial Aggregation of Non-Hodgkin's Lymphoma (NHL). A Case Report
por: Loves, Sandra SCM, et al.
Publicado: (2006)

Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma
por: Agool, Ali, et al.
Publicado: (2009)

Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases
por: Han, Lina, et al.
Publicado: (2010)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

The nuclear structure of $^{227}$Fr
por: Kurcewicz, W, et al.
Publicado: (1997)

Multiple Consecutive Infections Might Explain the Lack of Protection by BCG
por: Cardona, Pere-Joan, et al.
Publicado: (2014)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
por: Leisch, Michael, et al.
Publicado: (2020)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
por: Zeidan, Amer M., et al.
Publicado: (2022)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy
por: Liang, Guanghao, et al.
Publicado: (2023)

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
por: Saliba, Antoine N., et al.
Publicado: (2022)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study
por: van der Veen, Lucia, et al.
Publicado: (2021)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
por: Shukla, Deepak Kumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r8gh21rq1le6varuroeor6q4g1